News
-
Powder testing specialist Freeman Technology has announced that Managing Director Tim Freeman has received the Richard S. Ladd Standards Development Award from the ASTM for development of ASTM Standard Designation D7891 “Standard Test Method for… Read more . . .
-
Australian medical cannabis company MGC Pharmaceuticals has signed a collaboration agreement with Israeli device developer SipNose for development of a cannabinoid therapy for the treatment of epilepsy, the company said. The agreement includes an option… Read more . . .
-
A study published in the British Journal of General Practice titled “Overdiagnosis of asthma in children in primary care: a retrospective analysis” found that over half of children diagnosed with asthma at several major healthcare… Read more . . .
-
Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis… Read more . . .
-
Intranasal delivery specialist Impel NeuroPharma and the Toronto-based Centre for Addiction and Mental Health (CAMH) have signed a licensing agreement for an intranasal neuropeptide-based therapy for the treatment of depression. The peptide, which was discovered… Read more . . .
-
Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer’s acquisition offer, the company said. Alexza noted that the letter of intent allows the… Read more . . .
-
MannKind Corporation has announced the death of founder and Chairman Emeritus Alfred Mann at age 90, one week after he stepped down as Chairman of the Board. Mann served as CEO from November 2003 until… Read more . . .
-
Norwegian CDMO Curida, which offers a wide range of analytical, development, and manufacturing services for OINDPs, has announced a new strategic partnership with pharmAccel Consulting Director René Bommer. In July 2015, Curida acquired a nasal… Read more . . .
-
Adapt Pharma has announced the availability of Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose in the US. Narcan nasal spray was approved by the FDA in November 2015. In 17 of… Read more . . .
-
Health Canada has approved Teva Canada Limited’s application for its tobramycin inhalation solution, a generic version of Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Canada. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany